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Introduction: Treatment for advanced stage colorectal cancer with synchronous peritoneal carcinomatosis (PC) and
hepatic metastasis (HM) has progressed significantly over the past 10 years.
Case report: We present the case of a 39-year-old female patient with stage IV colorectal cancer with bilateral HM,
pulmonary oligometastatic disease, and diffuse PC who underwent hyperthermic intraperitoneal chemotherapy
(HIPEC) and complete cytoreductive surgery (CRS) for her intra-abdominal disease. The patient had an uneventful
immediate post-operative recovery, and subsequently tolerated multiple cycles of adjuvant chemotherapy and
percutaneous radiofrequency ablation of pulmonary lesions. At her 22-month follow-up assessment, the patient
remains alive with disease.
Conclusion: Current recommendations for surgical management of synchronous colorectal cancer PC and HM
indicate that patients with less than three HMs, a low peritoneal cancer index (PCI), and good functional status
will benefit most from CRS and HIPEC. Our patient had an elevated PCI of 12 as measured by computed tomography
imaging, and five HMs (all less than 3 cm in size); however, given that her life expectancy on systemic chemotherapy
was estimated to be approximately 12 months, we have observed carefully selected patients to benefit from an
aggressive multi-modality approach. This case report demonstrates an all too common scenario for surgeons
managing patients with advanced CRC, and highlights the importance of patient selection for surgical management as
part of multidisciplinary cancer care in this patient population.Background
Over 100,000 patients were diagnosed with colorectal
cancer (CRC) in 2012 in the United States, and it re-
mains the second leading cause of cancer-related death
[1]. Between 10 and 25% of patients with CRC are af-
fected by peritoneal carcinomatosis (PC) [2,3], and 35 to
55% will have hepatic metastasis (HM) during their dis-
ease course [4,5]. While significant progress has been
made in the independent management of HM and PC in
CRC patients, the presence of HM in patients with
known PC was traditionally considered a contraindica-
tion for cytoreductive surgery (CRS) [3,6].
Recent studies have suggested a survival benefit for
CRC patients with PC and HM with a combination of* Correspondence: diegoavicente@gmail.com
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duction (CC1) [7], hyperthermic intraperitoneal chemo-
therapy (HIPEC), and adjuvant systemic chemotherapy
in carefully selected patients [8-15].
We present the case of a CRC patient with PC and HM
who underwent multi-modality therapy consisting of CRS,
HIPEC, adjuvant chemotherapy, and percutaneous radio-
frequency ablation (RFA) of pulmonary lesions.Case presentation
A 39-year-old, otherwise healthy, mother of four pre-
sented with intermittent lower abdominal pain. After
diagnostic evaluation, she was found to have a partially
obstructing sigmoid colon adenocarcinoma, likely meta-
static hepatic lesions on her computed tomography (CT)
scan, and elevated serum carcinoembryonic antigenrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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sigmoid colectomy and a biopsy of the omental periton-
eal surface and left hepatic lesions in November 2012 at
an outside institution. A pathologic evaluation of the
resected colon specimen revealed moderately differenti-
ated adenocarcinoma (pT4aN2aM1b) with lymphovascu-
lar and perineural invasion, disease in four of 12
involved mesenteric nodes, distant metastasis to the
omentum, peritoneal surface, and liver, and positive mu-
tation in codon 13 of the K-ras gene. Upon confirmation
of peritoneal surface malignancy of colonic origin the
patient was referred to our Surgical Oncology depart-
ment for a consultation.
Further evaluation at our center revealed a persistently
elevated serum CEA (303 ng/ml), and cross-sectional
imaging revealed multiple R > L hepatic lesions (five in
total, all less than 3 cm in size), and peritoneal surface
disease, with an estimated Peritoneal Cancer Index (PCI)
score as measured by CT of 12 (Figure 1). Three separ-
ate 3-mm pulmonary nodules were also identified.
The patient was counseled extensively and given
her primary concern to extend time with her family
for any possible amount of time, her limited life ex-
pectancy if treated with systemic chemotherapy
alone, and the resectable nature of her metastatic
disease, the patient consented to proceed with multi-
modality therapy consisting of CRS with HIPEC and
pulmonary RFA, with intent to extend progression-
free survival.
In December 2012 the patient underwent CRS with
multi-visceral resection (right hepatectomy, wedge resec-
tion of the left liver, omentectomy, splenectomy, subtotal
colectomy, hysterectomy, bilateral salpingo-oophorectomy,
retroperitoneal lymphadenectomy, partial cystectomy,
and peritonectomy), and clearance of all grossly appar-
ent intra-peritoneal disease (CC0). After cytoreduction
we used bi-directional intraoperative chemotherapyFigure 1 Initial staging computed tomography scan at our institution
carcinomatosis indicated by arrows.consisting of intravenous 5-fluorouracil and leucovorin,
in conjunction with oxaliplatin-based HIPEC, over 35
minutes at a temperature of 42°C.
On post-operative day seven, the patient was dis-
charged home. Her immediate post-operative course was
uneventful. The patient tolerated six cycles of leucov-
orin, fluorouracil, and oxaliplatin (FOLFOX) adjuvant
systemic therapy with good response, as well as percu-
taneous CT-guided RFA of the metastatic pulmonary le-
sions in post-operative month five. In post-operative
month nine, the patient presented with a small bowel
obstruction secondary to a diaphragmatic hernia. The
diaphragmatic hernia was repaired, and a single retroperi-
toneal metastatic recurrence was identified and ablated
during this procedure. The patient maintained excellent
performance status (Eastern Cooperative Oncology Group
(ECOG) 0) throughout this portion of her care, though
she demonstrated progression of her pulmonary disease in
post-operative month 10 and received an additional seven
cycles of palliative systemic FOLFOX therapy. Progression
of the disease was again noted in post-operative month 13
and the patient was treated with pelvic radiation for a sa-
cral metastasis, RFA for pulmonary lesions, and leucov-
orin, fluorouracil, and irinotecan (FOLFIRI) systemic
therapy. The patient was transitioned to 5-fluorouracil
and bevacizumab, due to irinotecan-related toxicity, in
post-operative month 17. Though there was no further
evidence of intra-abdominal metastatic disease, the pa-
tient’s pulmonary disease progressed on this palliative sys-
temic therapy over a four-month period (Figure 2) and the
patient then transitioned to aggressive comfort care in
post-operative month 22.Conclusion
We present a patient with CRC with peritoneal surface
and visceral spread of the disease to the liver and lung.demonstrating multiple hepatic metastasis and peritoneal
Figure 2 Computed tomography scan images demonstrating progression of metastatic colorectal cancer pulmonary disease indicated
by arrows from the patient’s initial staging work up at our institution through her transition to aggressive comfort care.
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palliative care; (2) systemic chemotherapy alone; or (3)
aggressive multi-modality therapy with curative intent,
consisting of CRS with HIPEC and systemic chemother-
apy, as well as pulmonary lesion ablation and/or resection.
Patients with peritoneal surface malignancy of colorec-
tal origin and HM are carefully selected for CRS and
HIPEC based on a thorough review of comorbidities,
functional status (ECOG), extent of peritoneal surface
involvement (PCI), number, size, and distribution of
HM, as well as the ability to achieve complete resection
and/or ablation of disease [8,14]. Appropriate timing of
CRS and systemic therapy is also important for these pa-
tients. At this time, neoadjuvant chemotherapy for re-
sectable HM [16,17] or PC [18,19] from CRC has
demonstrated mixed results in the literature. Determin-
ation of optimal timing of treatment should be made
based on a multidisciplinary approach, particularly in
cases of resectable synchronous HM, PC, and pulmonary
metastasis of CRC origin.
Our patient was young, in excellent health, and with
excellent performance status at the time of presentation.
Her PCI and size and number of hepatic and pulmonary
metastasis made her a suitable candidate for consider-
ation of multi-modality therapy with curative intent. Es-
timated survival with modern systemic chemotherapy
alone is less than 13 months [3,20-23], whereas a median
survival of approximately 20 months (with a five-year
overall survival rate of approximately 30% may be
achieved in selected patients that undergo optimal cytor-
eduction in conjunction with regional chemotherapy.
Several reports have demonstrated the survival benefit
of CRS and HIPEC for CRC patients with combined PC
and HM [8-14], and a meta-analysis of these trials re-
vealed that CRS and HIPEC offers improved survival
compared to the expected survival with modern sys-
temic chemotherapy [15]. Three of these studiesreported on prognostic factors for survival after CRS
and intraperitoneal chemotherapy, as seen in Table 1.
Similar to CRC patients with only PC who undergo
CRS, poor prognostic factors for patients with PC and
HM who undergo surgery with curative intent include
high PCI (or Gilly classification) and inadequacy of re-
section. The largest series (n = 37) from these studies
noted that patients with a PCI ≥12 or three or more HMs
had a median overall survival of 27 months, which was
significantly shorter than those with a PCI <12 and one to
two HMs (median survival of 40 months) [14]. Of the
three patients in this study who, like our patient, had a
PCI ≥12 and three or more HMs, and required a major
liver resection, one patient died within the first postopera-
tive month, while the remaining two patients survived to
between 25 and 36 months. Other studies have also dem-
onstrated that patients with an elevated PCI who undergo
liver resection and adequate resection of intra-abdominal
disease (CC0 or CC1) who do not succumb to operative
mortality (during the first postoperative month) can
achieve survival for more than 13 months [8,11].
Beyond survival, a second major concern for patients
with PC and HM is the potential morbidity from the
addition of a major procedure to CRS. Interestingly, two
reports have demonstrated that the addition of hepatic
resection in this setting has not significantly increased
the morbidity compared to CRS for PC alone [12,14]. In
the case of our patient, she developed a left-sided dia-
phragmatic hernia after CRS, which was repaired in
postoperative month nine, and she subsequently had no
further intra-abdominal complications from the CC0 of
her extensive intra-abdominal pathology.
At this time, the patient has been transitioned to com-
fort care; however, she is thankful for the time she was
able to enjoy with her family (her primary concern) and is
alive with the disease at 22 months from her diagnosis,
which is beyond her estimated survival on systemic
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be achieved with CRS
and HIPEC in patients
with PCI <12 and HM <3.
As seen in studies evaluating CRS and HIPEC in PC patients only, the principal prognostic factors (1, 2, 3, 4) for patients with PC and HM were extent of peritoneal involvement and adequacy of resection.
*Though the majority of patients had both PC and HM, the authors did not differentiate patients with PC and HM from patients with PC and extra-hepatic metastasis in this study.
- Value not reported.
CC0: Complete Cytoreduction; CC1: near complete cytoreduction; CRS: Cytoreductive Surgery, HIPEC: Hyperthermic Intraperitoneal Chemotherapy; HM: Hepatic Metastasis, PC: Peritoneal Carcinomatosis, PCI: Peritoneal
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ning to define which metastatic CRC patients will benefit
most from CRS, the overall number of patients in these
studies remains limited (n <100). Hence patient selection
in conjunction with multidisciplinary consultation, thor-
ough informed consent, and careful consideration of
‘name the disease, stage the disease, assess resectability,
and determine operability’ by a capable team with exten-
sive experience with CRS and HIPEC are imperative.
Consent
Consent was obtained from the patient’s family for pub-
lication of this case report.
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